On August 7, SKB BIO rose 3.15% in regular trading, trading at 524.5 HKD/share, with turnover of approximately 74.77 million HKD.

On the news front, the company recently announced that its novel dual-payload ADC drug SKB565 received clinical trial approval from China's National Medical Products Administration (NMPA) for the treatment of advanced solid tumors. SKB565 is the company's first dual-payload antibody-drug conjugate to enter the clinical stage, marking a critical step in its integrated \"ADC+IO\" development strategy.

Meanwhile, the company's board is scheduled to convene on August 17 to review interim results for the six months ending June 30, fueling market expectations for earnings delivery. Goldman Sachs and JP Morgan previously raised their target prices to 582.95 HKD and 648 HKD respectively, both maintaining buy ratings. Multiple catalysts converging near the mid-year results window have driven heightened investor attention.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)